Systemic Therapeutics Corp. is a Canadian pre-clinical stage, biotechnology company specialized in the development of new therapies focusing on the master regulator of lipid metabolism, sterol regulatory-element binding proteins (SREBP), based on first-in-class small molecule SREBP inhibitors. The company aims to provide new treatment options for metabolic conditions such as dyslipidemia, via reduction of circulating PCSK9, and Non-Alcoholic Fatty Liver Disease. Systemic is pioneering a new approach to the care of metabolic disorders.